Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.

Abstract: Provided is a speaker, including a frame; a vibration unit fixed to the frame; and a magnetic circuit unit driving the vibration unit to vibrate and produce sound. The vibration unit includes a diaphragm and a voice coil; the diaphragm includes a first suspension, a second suspension and a vibrating portion; the magnetic circuit unit is provided with a magnetic gap, and the voice coil is inserted in the magnetic gap; the magnetic circuit unit includes a yoke; and the yoke and the diaphragm are arranged at two opposite sides of the frame; and the vibration unit further includes a fixing ring connected to the magnetic circuit unit; the second suspension surrounds the fixing ring; and the inner peripheral side of the second suspension is fixed to an end of the fixing ring close to the yoke. With this structure, the acoustic performance of the speaker is improved.

Abstract: A method includes storing, at a computing device, access granularity criteria associated with a memory area. The method further includes receiving a memory operation request requesting access to a first portion of the memory area at the first access granularity. The method further includes in response to the memory operation request satisfying the access granularity criteria, sending, from the computing device, a command to a storage device based on the memory operation request.

Abstract: Provided is a sounding device, including frame and vibration system and magnetic circuit unit fixed to the frame. The vibration system includes diaphragm, voice coil driving the diaphragm to vibrate and sound, holder fixed to diaphragm, and auxiliary diaphragm spaced from diaphragm. The holder includes holder main body, first connection portion formed from holder main body to magnetic circuit unit and second connection portion spaced from first connection portion. The voice coil is fixed to second connection portion. One end of the auxiliary diaphragm is fixed to frame. One end of first connection portion away from holder main body bends and extends away from second connection portion to form flange. One end of auxiliary diaphragm away from frame is fixed to flange. The sounding device may reduce accuracy deviation and hidden dangers of gluing failure caused by rear assembling of the auxiliary diaphragm.

Abstract: A contact lens system includes a shared antenna electrode, an accommodation actuator to provide variable optical power, and a controller coupled to the accommodation actuator and the shared antenna electrode. The controller including logic for arbitrating access to the shared antenna electrode between an impedance sensor and a communication circuit; selectively establishing an oscillator with the impedance sensor and the shared antenna electrode; correlating an oscillation condition of the oscillator to an accommodation setting; and adjusting the variable optical power of the accommodation actuator based upon the accommodation setting. An impedance across the shared antenna electrode varies based upon an amount an eyelid overlaps the contact lens system when the contact lens system is worn on an eye.

Abstract: The application discloses a vibration sounding device including a housing body with a containment cavity, a sounding unit placed in the containment cavity, a weight, a drive coil and a spring plate. The spring plate includes a first fixed section for fixed connection with the weight and a second fixed section for fixed connection with the housing body. The first fixed section and the second fixed section are fixed by laser spot welding. Compared with the prior art, the first fixed section and the second fixed section are fixed by laser spot welding, which can improve the bonding strength between the first fixed section and the second fixed section, and ensures the strength of the spring plate when the vibration sounding device is working.

Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fcy receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fcy receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.

Abstract: The present invention provides a multifunctional sounding device including a housing, a first vibration system, a second vibration system, a magnetic circuit system, an elastic component and a flexible circuit board. The elastic component includes a deformation part fixed to the second vibration system and an installation part extended from both ends of the deformation part and fixed to the housing. The second vibration system is suspended in the containment cavity through the elastic component. The flexible circuit board is connected with the elastic component, so that the vibration of the flexible circuit board is coupled with the vibration of the elastic component. Therefore, the damping of the elastic component is reduced, the force received by the elastic component during vibration is reduced, and the service life of the elastic component is extended.

Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.

Abstract: The present invention discloses a microcapsule powder stable in gastric acid, a method for preparing the same and use thereof. The microcapsule powder comprises a core material and a capsule material coated outside the core material, wherein the capsule material has a melting point of greater than 42° C., and the capsule material does not decompose or dissolve under the action of protease and gastric acid, but decomposes under the action of intestinal digestive enzymes. The core material is coated with the capsule material in the microcapsule powder, thus achieving high-efficiency coating of the core material by a single component. The microcapsule powder achieves conventional intragastric stability as well as favorable stability in an open environment at room temperature, thus solving the problem that the conventional embedding solution may only achieve intragastric stability, but the stability in an open environment at room temperature is low.

Abstract: An apparatus with a built-in self-test includes a sensor electrode, an impedance sensor coupled to the sensor electrode to measure a test impedance of the sensor electrode as influenced by an external load, a secondary electrode disposed adjacent to the sensor electrode to inductively couple with the sensor electrode and influence the external load on the sensor electrode, a first switch coupled to the secondary electrode to selectively change a second impedance of the secondary electrode, and a controller coupled to the impedance sensor and the first switch. The controller includes logic for adjusting the first switch to wirelessly load the sensor electrode with the secondary electrode in a predetermined impedance state, measuring the test impedance with the impedance sensor while the secondary electrode is in the predetermined impedance state, and comparing the measured test impedance against a threshold impedance range to perform a self-test.

Abstract: Disclosed is a characterization method of closed pores and connectivity of coal measure composite reservoirs, including collecting samples of coal seams and shales reservoirs, carrying out low-field NMR experiments and NMR freeze-thaw experiments on plunger samples and crushed samples with different particle sizes to obtain cumulative pore volume distribution and differential pore size distribution of the crushed samples, comparing crushed samples with plunger samples for optimal crushed particle sizes, and preliminarily determining a distribution range of closed pores; carrying out SAXS experiments on crushed samples to obtain size distribution and volume of total pores of 1-100 nanometers; calculating pore volume of total pores and closed pore volume in composite reservoirs by low-field NMR experiments results; carrying out non-steady overburden permeability experiments and variable factors on plunger samples of coal seams, shales and tight sandstone to characterize the connectivity under influence of pores

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: Methods, apparatuses, and computer-readable media are set forth for visualizing and interacting with well production data in a three-dimensional or four-dimensional environment, e.g., using a volumetric well production display representation representing a well in an oilfield and including a plurality of display characteristics configured to display historical production data for the well over a time period.

Abstract: Provide are a detector module, a detector, and a medical device. The detector module includes a plurality of detection sub-modules at least partially arranged in a stepped manner in a first direction. Each of the plurality of detection sub-modules includes a plurality of photoelectric conversion units arranged at intervals in a second direction intersecting with the first direction. One of two adjacent detection sub-modules is located at a higher step as a first detection sub-module, and the other one is located at a lower step and as a second detection sub-module. A first gap is formed between the plurality of photoelectric conversion units of the first detection sub-module. A second gap is formed between the plurality of photoelectric conversion units of the second detection sub-module. A width of the first gap in the second direction is smaller than a width of the second gap in the second direction.

Abstract: The application relates to a vibration sounding device including: a housing body with a containment cavity and a sounding unit arranged in the containment cavity. The sounding unit includes a vibration system and a magnetic circuit system. The magnetic circuit system includes a main magnet and a secondary magnet assembly. The vibration sounding device also includes an elastic assembly, a weight assembly, and a drive coil. The second direction is perpendicular to the first direction. By virtue of the configuration, it is beneficial to simplify the forming process of the weight assembly, reduce the production cost, and also facilitate the replacement of the drive coil.

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. Also, disclosed a pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a targeted therapy agent and the use thereof.

Abstract: The present disclosure provides a speaker including a housing and a vibration system and a magnetic circuit unit that are received in the housing. The magnetic circuit unit includes lower clamp plate and magnetic circuit assembly arranged on lower clamp plate. A central area of lower clamp plate abuts against bottom wall of the housing. An edge area of lower clamp plate is spaced from the bottom wall. The edge area is provided with flange portion bending and extending from lower clamp plate toward the bottom wall. The flange portion abuts against the bottom wall. The flange portion abuts against the bottom wall. In this way, when speaker falls off, flange portions come in contact with bottom wall, such that stability of magnetic circuit unit can be improved, then operational performance and service life can be improved.